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Abstract 
Background 
The majority of patients diagnosed with idiopathic rapid eye 
movement sleep behaviour disorder (iRBD) progress over time to 
a Lewy-type α-synucleinopathy such as Parkinson’s disease or 
dementia with Lewy bodies. This in vivo molecular imaging 
study aimed to investigate if extrastriatal monoaminergic 
systems are affected in iRBD patients and if this coincides 
with neuroinflammation.  
 
Methods 
We studied twenty-one polysomnography-confirmed iRBD patients 
with 18F-DOPA and 11C-PK11195 positron emission tomography (PET) 
to investigate extrastriatal monoaminergic function and 
microglial activation. Twenty-nine healthy controls (n=9 18F-
DOPA and n=20 11C-PK11195) were also investigated. Analyses 
were performed within predefined regions of interest and at 
voxel-level with Statistical Parametric Mapping.  
 
Results 
Regions of interest analysis detected monoaminergic 
dysfunction in iRBD thalamus with a 15% mean reduction of 18F-
DOPA Ki values compared to controls (mean difference = -
0.00026, 95% confidence interval [-0.00050 to -0.00002], p-
value = 0.03). No associated thalamic changes in 11C-PK11195 
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binding were observed. Other regions sampled showed no 18F-DOPA 
or 11C-PK11195 PET differences between groups. Voxel-level 
interrogation of 11C-PK11195 binding identified areas with 
significantly increased binding within the occipital lobe of 
iRBD patients. 
 
Conclusion 
Thalamic monoaminergic dysfunction in iRBD patients may 
reflect terminal dysfunction of projecting neurons from the 
locus coeruleus and dorsal raphe nucleus, two structures that 
regulate REM sleep and are known to be involved in the early 
phase of PD. The observation of significantly raised 
microglial activation in the occipital lobe of these patients 
might suggest early local Lewy-type α-synuclein pathology and 
possibly an increased risk for later cognitive dysfunction.  
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Introduction 
 
Pathology studies of Parkinson’s disease (PD) patients have 
reported degeneration in noradrenergic, serotonergic, and 
cholinergic nuclei and pathways in both subcortical and 
cortical brain regions [1-4], which is suggested to be 
connected to a variety of non-motor symptoms commonly observed 
in these patients [5]. Therefore, in vivo molecular imaging, 
which has traditionally been used to assess dopamine 
nigrostriatal dysfunction in PD patients, has also been 
employed to assess changes in extrastriatal regions containing 
monoaminergic innervation in these patients. Main observations 
in early stages of PD include thalamic monoaminergic 
dysfunction [6-9], and increased uptake in the midbrain raphe, 
internal globus pallidus, anterior cingulate gyrus, and 
prefrontal cortex [6, 7, 10-12]. Imaging studies in PD have 
also observed raised levels of microglial activation in both 
striatal and extrastriatal regions [13-17], suggesting an 
important role for neuroinflammation in the progression of the 
disease [18]. 
Idiopathic rapid-eye-movement sleep behaviour disorder (iRBD), 
a parasomnia characterised by failure to lose muscle tone 
during REM sleep leading to dream enactment behaviour [19], 
seems to be a prodromal stage of Lewy-type α-synucleinopathies 
characterised by parkinsonism and dementia [20-22]. Using 
positron emission tomography (PET), we have recently showed 
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that iRBD patients have raised levels of microglial activation 
in the substantia nigra along with a putaminal dopaminergic 
deficit. These findings provide further strong evidence that a 
large number of iRBD patients are in a prodromal stage of 
parkinsonism [23]. Interestingly, IRBD patients show a variety 
of non-motor symptoms similar to those seen in PD patients 
[24, 25], which in some instances might be related to 
monoaminergic changes in extrastriatal regions [5]. Therefore, 
in the current study, we aimed to investigate whether in vivo 
PET imaging detects changes in monoaminergic innervation in 
extrastriatal regions in iRBD patients similar to those 
reported in early PD, and whether these are accompanied by 
increased levels of microglial activation.  
 
 
 
Methods 
 
 
Study subjects 
 
 
This study was conducted between March 2015 and February 2017. 
The study protocol was approved by the Central Denmark Region 
Committee on Health Research and the ethics committee of the 
Hospital de Clínic Barcelona. All subjects gave informed 
written consent according to the Declaration of Helsinki 
before enrolment into the study. Twenty-one iRBD patients with 
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a polysomnography-confirmed diagnosis were recruited from 
tertiary sleep clinics at Aarhus University Hospital, Denmark 
and the Multidisciplinary Sleep Unit of the Hospital Clínic de 
Barcelona, Spain. Patients from Spain flew to Denmark to 
undergo PET examinations. All iRBD patients underwent both 18F-
DOPA and 11C-PK11195 PET and were compared to 29 healthy 
control subjects who underwent one of the two PET examinations 
(n=9 18F-DOPA PET and n=20 11C-PK11195 PET) [23, 26]. No 
patients or control subjects reported motor or cognitive 
problems.  
Since our original investigation of nigrostriatal function in 
iRBD patients [23] one additional iRBD patient has been 
recruited to this ongoing study. Additionally, to increase the 
power of the 11C-PK11195 PET analysis in extrastriatal areas, 
we have included 10 extra control subjects who had 11C-PK11195 
PET as part of another study performed in parallel to the 
current one at our Unit [26]. The PET scan was performed on 
the same scanner and with the same scan protocol.  
 
 
PET and MRI 
 
 
All subjects had PET and MRI scans performed as previously 
described [23]. For details, please see supplementary 
material. 
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Image quantification 
 
 
Extrastriatal monoaminergic innervation was assessed with 18F-
DOPA PET. 18F-DOPA uptake expressed as an influx constant (Ki 
value) reflects activity of the aromatic L-amino acid 
decarboxylase enzyme, which is present in most monoaminergic 
neurons [27, 28]. Thus, in regions with monoaminergic 
innervation i.e. dopaminergic, serotonergic or noradrenergic 
innervation, 18F-DOPA PET measures the overall status of the 
monoaminergic system [27].  
The level and extent of microglial activation was measured 
with 11C-PK11195 PET, which frequently has been used to examine 
microglial activation in Lewy-type α-synucleinopathies and 
other neurodegenerative disorders [13-16, 29, 30]. 
Parametric images were generated for both tracers. The Patlak 
graphical approach was used to calculate the 18F-DOPA influx 
constant (Ki value) and for 11C-PK11195 binding potentials 
(BPND) the simplified reference tissue model using an 
individual reference tissue non-specific input function 
extracted with a supervised cluster analysis was used [31]. 
For details, please see supplementary material. 
 
Region of interest analyses 
 
 
Region of interest analysis was performed with PNEURO PMOD 
software v 3.6 (Pmod technologies Ltd., Switzerland) as 
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previously described [23]. For details, please see 
supplementary material.  
Regions of interest were predefined and selected based on a 
combination of previous observations of 18F-DOPA (monoaminergic 
marker) [6, 7, 10-12] and 11C-DASB (serotonin transporter 
marker) [8, 9] changes in early stage PD, the Braak PD Lewy 
pathology staging scheme [32], and previous observations of 
raised microglial activation in PD or dementia with Lewy body 
patients (DLB) [13, 15-17]. Extrastriatal regions of interest 
sampled included: locus coeruleus, median raphe nucleus, 
dorsal raphe nucleus, hypothalamus, thalamus, globus pallidus 
internal, anterior cingulate gyrus, frontal lobe, and 
occipital lobe. Values from left and right side are averaged. 
The occipital lobe was not sampled with 18F-DOPA as this was 
the reference region for non-specific uptake of this tracer.  
Assessment of 18F-DOPA Ki values and 11C-PK11195 BPND in 
nigrostriatal regions of interest has previously been reported 
(iRBD n=20, controls n=19) [23]. In the current study, we 
assessed whole striatum 18F-DOPA uptake (iRBD n=21), which 
consisted of averaged putamen and caudate 18F-DOPA Ki values 
from both left and right side. Whole striatum 18F-DOPA uptake 
was used to assess the relationship between dopaminergic 
nigrostriatal dysfunction and monoaminergic dysfunction in 
extrastriatal areas. 
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Statistical parametric mapping analysis 
 
Following region of interest analysis, Statistical Parametric 
Mapping (SPM12; Wellcome Trust Centre for Neuroimaging, 
London, UK) was performed to localise significant changes in 
tracer uptake/binding at a voxel level within the previously 
defined extrastriatal regions of interest. Using this method, 
differences in 18F-DOPA Ki value or 11C-PK11195 BPND between 
iRBD patients and controls can be examined in each voxel 
included within the region of interest analysis. Previous 18F-
DOPA PET studies in PD patients have shown changes in voxels 
confined to smaller areas. These changes may be less extensive 
compared to those detected in a region of interest analysis 
encompassing larger volumes, however, not less important.  
For details, please see supplementary material. 
 
Statistical analysis 
 
 
Statistical analysis and graphical presentations were 
performed in Stata IC 14.2 (StataCorp LP. TX, USA) and 
GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). 
Normal distribution of variables was examined with qnorm-plots 
and the D’Agostino Shapiro-Wilks test. Group differences in 
18F-DOPA Ki values and 11C-PK11195 BPND were interrogated with a 
parametric two-tailed Student’s t test (alpha = 5.0%) when 
data were normally distributed and with a non-parametric 
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Wilcoxon / Mann-Whitney rank test when this was not the case. 
Correlations between 18F-DOPA Ki and 11C-PK11195 BPND within 
regions of interest were interrogated with a two-tailed 
Pearson product-moment or Spearman rank correlation 
(alpha=5.0%). Correlations between striatal and extrastriatal 
18F-DOPA uptake were only performed if an extrastriatal region 
showed a significant change in 18F-DOPA uptake in iRBD patients 
compared to controls. 
 
 
 
 
 
 
Results 
 
 
Twenty-one polysomnography-confirmed iRBD patients, 18 men and 
three women, with a mean age of 66.2 years (SD=6.3) at time of 
examination and 3.6 (SD=3.4) years from iRBD diagnosis, with a 
Montreal Cognitive Assessment (MoCA) score of 25.7 
(SD=2.4)(Table 1) and 29 healthy control subjects, 21 men (n=9 
18F-DOPA and n=12 11C-PK11195) and eight women (n=8 11C-
PK11195), with a similar age (n=9 18F-DOPA 64.6 ± 3.6 years, 
n=20 11C-PK11195 66.8 ± 6.0 years)and MoCA score 26.5 (SD=2.3)   
were included in the current study.  
Region of interest analysis detected a significant mean 
reduction of 15% in 18F-DOPA Ki values in the thalamus of iRBD 
patients compared to controls (mean difference = -0.00026, 95% 
confidence interval [-0.00050 to -0.00002], p-value = 0.03). 
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In all other extrastriatal regions of interest assessed, no 
difference was observed between groups (Figure 1 and Table 2).  
Comparisons for 18F-DOPA uptake at a voxel level within 
predefined extrastriatal regions of interest did not show any 
significant difference between iRBD patients and controls with 
the predetermined threshold (p < 0.01 and family-wise error 
correction p<0.05 at the cluster level). However, when we 
lowered the threshold of significance to that of the region of 
interest analysis (p < 0.05) we again detected clusters of 
decreased 18F-DOPA uptake in the thalamus of iRBD patients 
compared to controls, confirming the findings of the region of 
interest analysis. 
 
Extrastriatal 11C-PK11195 binding was similar between groups in 
the region of interest analysis (Figure 1). Voxel-level 
analysis of 11C-PK11195 binding detected areas of significantly 
increased signal in the occipital lobe of iRBD patients 
compared to controls, cluster size = 11629 and 11521 voxels 
(Figure 2). Within these areas, voxels with the strongest 
difference in 11C-PK11195 binding were localised to the visual-
associative area bilaterally (Brodmann area 18). This finding 
was not correlated to the MoCA score of iRBD patients, 
additionally, iRBD patients who drew the cube incorrect (n=9) 
in the visuoconstructional skill test of the MoCA had similar 
11C-PK11195 binding in the occipital lobe cluster identified by 
voxel-analysis compared to iRBD patients who drew the cube 
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correct (n=12) (p value = 0.81, mean 11C-PK11195 BPND, iRBD 
incorrect = 0.086, mean iRBD correct = 0.077) (Figure 2). 
 
No correlations were observed between 18F-DOPA Ki and 11C-
PK11195 BPND within the regions of interest investigated. 
However, a significant positive correlation was found between 
thalamic and whole striatum 18F-DOPA uptake, Pearson 
correlation r=0.52 (95% CI 0.11 to 0.78), p=0.016 (Figure 3). 
 
 
 
Discussion 
 
 
In this study, we have used PET imaging to assess whether iRBD 
patients have dysfunctional monoaminergic innervation and/or 
the presence of microglia activation in extrastriatal brain 
regions similar to those reported in early stage PD. Patients 
with iRBD are thought to represent a prodromal phenotype of a 
Lewy-type α-synucleinopathy disorder and so could already have 
some pathological features distinctive of these disorders, 
namely Lewy-type α-synuclein deposition in the peripheral 
autonomous nervous system [33-35], reduced dopaminergic 
innervation in the striatum [23, 36] and microglial activation 
within the substantia nigra [23]. We found significantly 
reduced 18F-DOPA uptake in the thalamus and increased 
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microglial activation in the occipital lobe of iRBD patients 
compared to controls. 
PET studies of PD patients with short disease duration have 
previously observed reduced thalamic 18F-DOPA Ki values 
(monoaminergic marker) [6, 7], and reduced thalamic 11C-DASB 
binding (serotonin transporter marker) [8, 9]. Additionally, 
reduced thalamic 11C-RTI-32 binding (noradrenergic and 
dopaminergic transporter marker) has also been reported in PD 
patients with depression [37]. Our observation of thalamic 
monoaminergic dysfunction in iRBD patients, detected with 18F-
DOPA PET, occurring prior to onset of parkinsonism, is a novel 
finding which could contribute to the understanding of the 
developing neurodegenerative process in Lewy-type α-
synucleinopathies. 
Whilst 18F-DOPA PET allows us to assess the presence of overall 
thalamic monoaminergic dysfunction, it does not allow a 
separate evaluation of dopaminergic, noradrenergic or 
serotonergic function in isolation in this structure.  Neither 
will PET evaluate glutamate, glycine or GABA levels; these 
transmitters are released from the subcoeruleus and 
gigantocellular nucleus and reach the thalamus and are 
essential pathways for the maintenance of normal REM sleep 
atonia [38, 39]. 
The density of dopaminergic axon terminals within the thalamus 
is limited with the exception of the pulvinar [40, 41]. Given 
this, dopaminergic changes will have a small impact on the 
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overall thalamic monoaminergic innervation. In contrast, both 
the predominantly noradrenergic locus coeruleus and the 
serotonergic caudal raphe nucleus send extensive projections 
to thalamus [40, 42], and early dysfunction in these brainstem 
nuclei could account for the observed reduction in thalamic 
18F-DOPA uptake. This may be supported by post-mortem 
pathological observations of Lewy-type α-synuclein pathology 
in these brainstem nuclei in iRBD patients [43] similar to 
that seen in Braak stage II PD [32]. Additionally, the locus 
coeruleus plays a role in REM sleep origin and maintenance 
[38, 44-47] and in vivo MRI changes in the locus coeruleus 
have been found in iRBD patients [48].  
18F-DOPA and 11C-PK11195 PET detected no group-level 
abnormalities in either locus coeruleus or raphe nucleus in 
our iRBD patients, which might argue against early 
involvements of these structures. Still, it should be noticed 
that similar observations were present in PET studies of early 
stage PD patients.  In these studies - monoaminergic and 
serotonergic reductions in tracer uptake in the thalamus 
preceded reductions in the locus coeruleus and raphe nucleus 
that did not occur until later disease stages [6, 7, 9]. 
Additionally, compensatory upregulation in the activity of the 
enzyme aromatic L-amino acid decarboxylase, which 18F-DOPA Ki 
reflects, is reported in early stage PD [6, 7, 10] and this 
may well retain 18F-DOPA Ki values within the normal range and 
thereby underestimate the true degree of dysfunction. Another 
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explanation for the apparent disparity between reduced 18F-DOPA 
Ki values in thalamic axonal terminals but not in the cell 
bodies of the locus coeruleus and raphe nucleus could be 
impaired axonal transport leading to dying back of axons, an 
early abnormal phenomenon occurring in the terminals in PD 
[49, 50].  
The clinical impact of early monoaminergic dysfunction in the 
thalamus in the presumed prodromal phase of Lewy-type α-
synucleinopathies needs to be clarified in future studies. It 
might be an early sign of future development of cognitive 
dysfunction [51, 52] as noradrenergic innervation from the 
locus coeruleus is believed to facilitate prefrontal cortex 
function and so mediate executive behaviour [53].  
 
Other extrastriatal regions of interest assessed in this study 
showed no significant decrease or increase at a group level. 
Previous 18F-DOPA PET studies in early stage PD patients have 
occasionally observed increased uptake in the midbrain raphe, 
internal globus pallidus, anterior cingulate gyrus, and 
prefrontal cortex, which is interpreted as components of an 
early compensatory mechanism [6, 7, 10-12]. It might be that 
the group of iRBD patients examined in this study are more 
heterogeneous in terms of their prodromal disease stages (3.6 
years (SD=3.4), this would decrease our power to detect subtle 
changes at this stage compared to a possible more homogenous 
study population like early PD patients. 
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Analysis of 11C-PK11195 showed similar binding potentials in 
iRBD patients and controls in all regions of interest assessed 
(Figure 1). However, voxel-wise analysis, which enables the 
detection of more localised changes in tracer binding, 
particularly in large cortical areas, identified bilateral 
clusters of significantly raised levels of microglial 
activation in the occipital lobe (visual associative cortex) 
of iRBD patients compared to controls (Figure 2). This is a 
novel finding in iRBD, which is in line with observations in 
PD [15-17], and fits well with previous observations of 
diffuse occipital glucose hypometabolism [54-56]  and reduced 
blood flow in iRBD patients [57]. Though, it should be noted 
that some studies did not observe this reduced occipital blood 
flow [58, 59]. Occipital neuroinflammation in iRBD may suggest 
the presence of local Lewy-type α-synucleinopathy and possibly 
reflect early signs of future cognitive changes. This view is 
supported by previous 11C-PK11195 PET studies observing raised 
occipital microglial activation in patients with PD dementia 
[60, 61] and DLB [16]. However, the effective clinical 
relevance of our finding remains to be investigated.  It 
should be noted that iRBD patients with no cognitive 
complaints often show abnormalities linked to visuospatial 
dysfunction and the occipital lobe on neuropsychological 
testing [62, 63]. In our cohort, the occipital 
neuroinflammation observed in iRBD patients did not correlate 
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with the MoCA score, moreover, similar levels of microglial 
activation was found between patients who drew the cube 
correct or incorrect in the MoCA visuoconstructional skill 
sub-item (Figure 2). Our findings could suggest that a raised 
level of microglial activation is not associated with 
cognitive decline at this prodromal stage of PD/DLB. However, 
it is also possible that we were underpowered to detect a 
significant correlation and that we need a larger study 
population with a wider range of MOCA scores. More specific 
and sensitive measures of visuospatial skills should be 
performed in future studies. Besides this, it should be 
mentioned that a previous observation in PD patients did not 
find an association between levels of microglial activation 
and clinical test scores [17], though, DLB patients in 
comparison to PD patients do have significantly higher levels 
of microglial activation [16], which could suggest that 
microglial activation is more strongly activated when 
cognition is severely impaired. Alternatively, occipital 
neuroinflammation at this prodromal stage could contribute to 
the vivid imagery of the dreams occurring in REM sleep, which 
is thought  to be related to occipital lobe activation in REM 
sleep.[64]. 
 
This study has limitations which should be acknowledged: 
First, 18F-DOPA PET enables us to obtain important knowledge 
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about the overall function of the monoaminergic innervation in 
the brain structures but does not allow examination of each 
separate component of monoaminergic neurotransmitter systems 
in brain structures with mixed dopaminergic, noradrenergic and 
serotonergic innervation. Second, 18F-DOPA region of interest 
results might be prone to a statistical type I error since 
correction for multiple testing was not performed, yet our 
finding of reduced 18F-DOPA in the thalamus is in line with 
previous observations in early stage PD patients and therefore 
most likely a genuine finding. Third, 11C-PK11195 yields a 
lower specific to background signal ratio than newer 
translocator protein ligands; this might have reduced 
sensitivity to detect subtle increases in microglial 
activation. Nevertheless, we chose 11C-PK11195 since it allows 
us to compare our observations with those of previous studies 
in Lewy-type α-synucleinopathies. Moreover, we avoid the issue 
of newer microglial tracers where translocator protein 
polymorphisms carried by individual subjects influence the 
tracer binding affinity, which potentially can lead to a 
selection bias. Finally, a relatively small number (n=9) of 
18F-DOPA controls were included.  
 
In summary, this study observed reduced monoaminergic axonal 
terminal function in the thalamus of iRBD patients, a finding 
which suggests dysfunction of monoaminergic terminals 
projecting from the locus coeruleus and raphe nucleus. These 
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nuclei regulate REM sleep and are observed to contain Lewy-
type α-synuclein pathology in iRBD patients and in the early 
developing disease phase of PD. Furthermore, clusters of 
significantly raised microglial activation were present 
bilaterally in the occipital lobe of our patients, a finding 
which might reflect early Lewy-type α-synuclein pathology and 
possibly an increased risk for later cognitive dysfunction and 
altered perception. These findings shed light on early disease 
processes in developing Lewy-type α-synucleinopathies, but the 
full clinical impact of these findings require clarification 
by adequate follow-up studies of these patients. 
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Tables 
 
Table 1 
Demographic and clinical characteristics 
 iRBD patients 
(n=21) 
Female / male 3 / 18 
Age (years) 66.2 (6.3) 
Time since iRBD diagnosis (years) 3.6 (3.4) 
Unified Parkinson’s Disease Rating Scale (part 
III) 
3.4 (2.3) 
Montreal Cognitive Assessment Score  25.7 (2.4) 
MoCA score < 26 and <21 n=10 and n=1 
SCOPA-AUT score 16.6 (8.1) 
University of Pennsylvania Smell 
Identification Test 
19.0 (7.5) 
Values are mean and brackets indicate standard deviation. 
iRBD = idiopathic REM sleep behaviour disorder 
Table 2 
18F-DOPA Ki values and 11C-PK11195 binding potentials in regions 
of interest in iRBD patients and control subjects 
ROI 18F-DOPA Ki value 11C-PK11195 BPND 
 Controls iRBD Difference Percenta
ge 
change 
p 
value 
Controls iRBD p 
value 
 Mean 
(95% CI) 
Mean 
(95% CI) 
   Median Median  
Locus 
coeruleus 
0.00428 
(0.00373 to 
0.00483) 
0.00423 
(0.00378 to 
0.00469) 
-0.00005 
(-0.00081 to 
0.00071) 
-1.2% 0.90 0.0830 0.0524 0.99 
Median raphe 0.00543 
(0.00408 to 
0.00679) 
0.00521 
(0.00462 to 
0.00580) 
-0.00022 
(-0.00140 to 
0.00096) 
-4,1% 0.70 0.160 0.2166 0.80 
Dorsal raphe 0.00613 
(0.00549 to 
0.00677) 
0.00581 
(0.00524 to 
0.00637) 
-0.00032 
(-0.00113 to 
0.00061) 
-5.3% 0.48 0.2304 0.2180 0.80 
Hypothalamus 0.00514 
(0.00454 to 
0.00574) 
0.00490 
(0.00457 to 
0.00524) 
-0.00024 
(-0.00085 to 
0.00037) 
-4,6% 0.43 0.0705 0.0180 0.46 
Thalamus 0.00176 
(0.00156 to 
0.00195) 
0.00149 
(0.00135 to 
0.00163) 
-0.00026 
(-0.00050 to -
0.00002) 
-15.0% 0.03 0.2048 0.2180 0.89 
 
Globus 
pallidus 
internal 
0.0034 
(0.0029 to 0.0038) 
0.0038 
(0.0035 to 
0.0042)  
0.00046 
(-0.0002 to 
0.0011) 
13.7% 0.14 0.1350 
 
0.1390 0.89 
 
Anterior 
cingulate 
gyrus 
0.00196 
(0.00170 to 
0.00222) 
0.00207 
(0.00184 to 
0.00229) 
0.00011 
(-0.00027 to 
0.00048) 
5.6% 0.55 0.1060 0.0883 0.37 
 
Frontal lobe 0.00104 
(0.00092 to 
0.00115) 
0.00107 
(0.00095 to 
0.00119) 
0.00004 
(-0.00016 to 
0.00023) 
3.6% 0.70 0.0484 0.0387 0.45 
Occipital 
lobe 
     0.0314 0.0470 0.10 
  
iRBD = idiopathic REM sleep behaviour disorder (n=21). 
Controls 18F-DOPA (n=9). Controls 11C-PK11195 (n=20).  
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Figures 
Figure 1 
18F-DOPA Ki values and 11C-PK11195 binding potentials in regions 
of interest 
 
 
Scatter-plot with individual subjects 18F-DOPA Ki values in 
regions of interest, blue symbols are controls (n=9) and red 
symbols are iRBD patients (n=21), bar indicates the mean value 
of the group and whiskers are one standard deviation (A). 11C-
PK11195 BPND in regions of interest, blue symbols are controls 
(n=20) and red symbols are iRBD patients (n=21), bar indicates 
the median value of the group (B). All values are provided in 
Table 2. 
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Figure 2 
Increased occipital 11C-PK11195 BPND in iRBD patients compared 
to controls 
 
 
Localisation of voxels with significantly increased 11C-PK11195 
BPND in the iRBD group compared to controls identified by 
Statistical Parametric Mapping analysis (A) and scatter-plot 
of individual 11C-PK11195 BPND across the two significant 
clusters localised by Statistical Parametric Mapping analysis 
(B). Bar indicates the mean value. Red dots indicate iRBD 
subjects who drew the cube incorrect in the 
visuoconstructional skill test of the Montreal Cognitive 
Assessment. 
 
 
Region Peak-level Cluster-level 
iRBD (n=21) compared to controls (n=20) 
 T-
score 
Coordinates 
 
    X             Y              
Z 
 
p-value 
 
(FWE-corrected at 
cluster level) 
p-value 
 
(uncorrected) 
Cluster 
size 
 
(voxels) 
Left visual 
associative cortex 
5.03 -24 -100 -10 0.000 0.000 11629 
Right visual 
associative cortex 
4.89 27 -95 -7 0.000 0.000 11521 
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Figure 3 
Correlation between 18F-DOPA Ki values in thalamus and whole 
striatum in iRBD patients 
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